Open an account

Iovance Biotherapeutics

IOVA · NASDAQ

$14.86+$0.65 (+4.57%)TodayMarket closed ·
Prev close $14.21

About IOVA

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 975 full-time employees. The company went IPO on 2008-06-20. The firm is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. The company is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer.

Employees
975
Headquarters
San Carlos, California
Listed
Jun 20, 2008
Sector
Health Care
Industry
Biotechnology
Website
iovance.com

IOVA key statistics

Market cap
6.73B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
17.29M
Volume
9.75M
Open price
$14.10
High today
$14.96
Low today
$13.83
52 Week high
$15.30
52 Week low
$1.76

Iovance Biotherapeutics (IOVA) at a glance

Iovance Biotherapeutics (IOVA) last traded at $14.86, with a market cap of 6.73B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $13.83 and $14.96. The current price is 7.4% above the day's low and 0.6% below its high.

Volume so far is 9.75M shares, below the average of 17.29M shares a day.

Over the past year Iovance Biotherapeutics has ranged from $1.76 to $15.30, and now sits 97% of the way up that range.

Iovance Biotherapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.11 per share against an estimate of -$0.1283.

The average analyst price target is $13.06, 12.1% below the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 10 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 12 analystsAvg $13.06
Low
$6.06
Now
$14.86
High
$21.00

IOVA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 8.0% on average.

  1. Q3 FY24: reported -$0.28 per share against an estimate of -$0.3052
  2. Q4 FY24: reported -$0.26 per share against an estimate of -$0.2725
  3. Q1 FY25: reported -$0.36 per share against an estimate of -$0.2441
  4. Q2 FY25: reported -$0.33 per share against an estimate of -$0.2902
  5. Q3 FY25: reported -$0.25 per share against an estimate of -$0.2632
  6. Q4 FY25: reported -$0.18 per share against an estimate of -$0.1751
  7. Q1 FY26: reported -$0.19 per share against an estimate of -$0.1528
  8. Q2 FY26: reported -$0.11 per share against an estimate of -$0.1283

IOVA news

  • Transcript: Iovance Biotherapeutics Q2 2026 Earnings Conference Call

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • Henry Khederian

    Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?

  • Shivdeep Dhaliwal

    Fair Issac Corp., Iovance Biotherapeutics, Stablecoin Development Corp., Carnival Corp. and Micron: Why These 5 Stocks Are on Investors' Radars Today

  • Vandana Singh

    Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars

  • Press releaseGlobe Newswire

    High-Stakes October has these Biotechs Entering Crucial Stretch

  • Avi Kapoor

    Crude Oil Down 1%; US Job Openings Fall In August

  • Press releaseGlobe Newswire

    Iovance Biotherapeutics to Present at Upcoming Conferences

Similar companies

Companies in the same industry as Iovance Biotherapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.